Shares of Zogenix Inc. (ZGNX) are up over 20% in pre-market trading on Thursday, following positive top-line results from its second confirmatory phase III study of its investigational drug, ZX008 for the treatment of children and young adults with Dravet syndrome.
from RTT - Biotech https://ift.tt/2zv3c1N
via IFTTT
No comments:
Post a Comment